CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Don’t miss our latest news! Sign up today for our free newsletter.
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Chiron Corp. announced Wednesday that it is ending the development of three compounds, including a recombinant form of interleukin-2 being studied in a Phase III trial for the treatment of patients with HIV. The company had been expected to complete the clinical trial, including patient follow-up, in 2007. Chiron is now reviewing data for a possible regulatory submission for approval of IL-2 only in a small subset of HIV-positive patients who do not receive any response to other anti-HIV medications. The company also stopped development of compounds intended to treat cystic fibrosis and hepatitis B.
From our Sponsors
Most Popular
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
Don’t miss our latest news! Sign up today for our free newsletter.
Watch Now: Advocate Channel
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Latest Stories
Elon Musk Agrees to Libs of TikTok Request for X ‘Data Dump’ on Anti-Defamation League
September 06 2023 11:12 AM